Top

Annals of Surgical Oncology

Published in:

01-12-2007 | Original Papers

A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study

Authors: H. Z. Malik, S. Farid, A. Al-Mukthar, A. Anthoney, G. J. Toogood, J. P. A. Lodge, K. R. Prasad

Published in: Annals of Surgical Oncology | Issue 12/2007

Abstract

Background

The aim of this study was to analyze the outcome of patients that received neoadjuvant chemotherapy prior to resection for colorectal liver metastases (CRLM) and compare them with a matched cohort of patients that underwent resection followed by adjuvant chemotherapy.

Methods

687 patients have undergone curative resection between January 1993 and January 2006. In this period, 84 patients received neo-adjuvant chemotherapy and 71 of this group went on to resection. A control group was chosen, matched with these patients, made up of patients who underwent resection followed by adjuvant chemotherapy.

Results

There was no difference in clinico-pathological features between the neoadjuvant and the control group. However patients in the control group had more-extended resections and longer hospital stays than those in the neoadjuvant group (p = 0.015). Patients in the control group had an increased incidence of early recurrences (p < 0.001). Despite this, there was no significant difference in either the cancer-specific or the disease-free survival between the two groups of patients.

Conclusion

Neoadjuvant chemotherapy has a role in the management of patients with disease that is considered initially unresectable as a down-sizing technique. In patients with resectable disease, the test-of-time approach that neoadjuvant therapy offers is yet to be proven.

Cancer Research UK Information Centre (2003) CancerStats. http://www info.cancerresearchuk.org/cancerstats

Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Canc 2006; 94: 982–999CrossRef

Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198–1206; discussion 1206PubMedCrossRef

Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38–46PubMedCrossRef

Fortner JG, Blumgart LH. A historic perspective of liver surgery for tumors at the end of the millennium. J Am Coll Surg 2001; 193: 210–222PubMedCrossRef

Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397–406; discussion 406–397PubMedCrossRef

Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–318; discussion 318–321PubMedCrossRef

Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198–1206; discussion 1206PubMedCrossRef

Heriot AG, Karanjia ND. A review of techniques for liver resection. Ann R Coll Surg Engl 2002; 84: 371–380PubMedCrossRef

10.

Malik HZ, Hamady ZZR, Adair R, Finch R, Al-Mukhtar A, Toogood GJ, Prasad KR, Lodge JA. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol 2006 (In press)

11.

Zaed Z R Hamady, Hassan Z Malik, Robert Finch, Robert Adair, Ahmad Al-Mukhtar, K Rajendra Prasad, Giles J Toogood, J Peter A Lodge. Hepatic resection for colorectal metastasis: impact of tumor size. Ann Surg Oncol 2006 (In press)

12.

Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888–4896PubMedCrossRef

13.

Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–520; discussion 520–502PubMedCrossRef

14.

Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663–669PubMedCrossRef

15.

Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347–353PubMedCrossRef

16.

Adam R, Pascal G, Castaing D. Tumor progression while on chemotherapy: a contraindication to liver resection for contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240 (6):1052–61; discussion 1061–4PubMedCrossRef

17.

Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 2006; 93 (8):1001–6PubMedCrossRef

18.

Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845–853PubMedCrossRef

19.

Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065–2072PubMedCrossRef

20.

Chang AE, Schneider PD, Sugarbaker PH et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685–693PubMedCrossRef

21.

Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418PubMedCrossRef

22.

Pohlen U, Rieger H, Mansmann U, Berger G, Buhr HJ. Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases. Anticancer Res 2006; 26: 3957–3964PubMed

23.

Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2003; 14(9): 1450–1451CrossRef

24.

Ho-Wing M, Ma B, Mok-Tony, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med-Oncol 2005; 22(3): 303–312

25.

H.Z. Malik, D. Gomez, V. Wong et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol 2007 (In press)

Title: A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study
Authors: H. Z. Malik
S. Farid
A. Al-Mukthar
A. Anthoney
G. J. Toogood
J. P. A. Lodge
K. R. Prasad
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9533-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2007

Editorial: More Answers About Prophylactic Mastectomy

Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma

Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional Analysis

L1 Is Associated With Favorable Outcome in Neuroblastomas in Contrast to Adult Tumors

Intrahepatic Lymphatic Invasion Independently Predicts Poor Survival and Recurrences after Hepatectomy in Patients with Colorectal Carcinoma Liver Metastases

Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities